BRK-A vs HQL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BRK-A shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.
Compare Another Pair
Related Comparisons
BRK-A vs HQL: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-A) and Abrdn Life Sciences Investors (HQL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.